Nanobiotix risk profile
80 Acute at or past the historical limit
Measured 21 October 2026 from NBTX's filed statements. Recomputed nightly.
80 (Acute), driven by Cash conversion at 100, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Volatile | One-year price volatility — 90.3% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 94 | Acute | Stable | Net debt to EBITDA |
| Competitive position | 69 | Stretched | Stable | Operating-margin gap against peers — -40.2 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.